IDSA : View All FDA Alerts

Search More FDA

02/01/2017

New FDA Drug Safety Communication on chlorhexidine gluconate - Drug Information Update

New FDA Drug Safety Communication on chlorhexidine gluconate- Drug Information Update

01/16/2017

FDA MedWatch - ED-3490TK Video Duodenoscope by Pentax: FDA Safety Communication - UPDATE

FDA Alert

01/12/2017

FDA MedWatch - Duodenoscopes by Fujifilm Medical Systems: Safety Communication - Certain Older Models Removed From Clinical Use

FDA Alert

10/03/2016

Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. HBV reactivation usually occurred within 4-8 weeks.

05/19/2016

Nizoral ketoconazole Oral Tablets: Prescribing for Unapproved Uses including Skin and Nail Infections Continues; Linked to Patient Death

FDA Alert

02/27/2012

FDA Approves First H. pylori Breath Test for Children

FDA Alert

01/04/2012

FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older

FDA Alert

11/18/2011

FDA Approves First Supplemental Test for Chagas Disease

FDA Alert

09/28/2011

FDA Clears First Single Use Face Mask for Children

FDA Alert

08/03/2011

Diflucan (fluconazole): Long-term, High-dose Use During Pregnancy May Be Associated With Birth Defects

FDA Alert

FDA approves new drug to treat adults with chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis

The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.

FDA approves new fluoroquinolone antibiotic to treat bacterial skin infections

The U.S. Food and Drug Administration today approved Baxdela (delafloxacin), a new antibacterial drug to treat acute bacterial skin and skin structure infections. Baxdela is available for intravenous and oral use.

FDA issues final rule on safety and effectiveness of antibacterial soaps

FDA Alert

FDA Advises Testing for Zika Virus in All Donated Blood in the US

FDA Alert

July 2016 Safety Labeling Changes posting includes 52 products

FDA Alert

FDA approves first generic version of widely used influenza drug

FDA Alert

Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects

FDA Alert

FDA announces voluntary nationwide recall of oral liquid docusate sodium manufactured by PharmaTech and distributed by Rugby Laboratories

FDA Alert

Stӧckert 3T Heater-Cooler System by Sorin Group Deustchland GmbH: Safety Communication - Reports of Mycobacterium Chimaera Infections

FDA Alert

Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections

FDA Alert

FDA Evaluating Study Examining Use of Oral Fluconazole (Diflucan) in Pregnancy

FDA Alert

Focus Diagnostics Laboratory Examination Kits: Class I Recall - Inaccurate Test Results

FDA Alert

FDA approves new treatment for inhalation anthrax

FDA Alert

Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection

FDA Alert

FDA approves new drug for treatment of chronic hepatitis C genotypes 1 and 4

FDA Alert

L.G Compounded Asafoetida Powder Recall

FDA Alert

Kaletra product labeling was updated

FDA Alert

Product Remova/lFoodborne Illness Outbreak Investigation Advisory

FDA Alert

FDA approves new antifungal drug Cresemba

FDA Alert

FDA approves new antibacterial drug Avycaz

FDA Alert

New data shows test can help physicians remove patients with suspected TB from isolation earlier

FDA Alert

Approval changes to the Kaletra label

FDA Alert

FDA approves a second vaccine to prevent serogroup B meningococcal disease

FDA Alert

Don't Inject Patients with IV solutions from Wallcur

FDA Alert - updated 1/14/15

FDA approves new antibacterial drug Zerbaxa

FDA Alert

FDA approves Viekira Pak to treat hepatitis C

FDA Alert

Dietary Supplements Containing Live Bacteria or Yeast in Immunocompromised Persons: Warning - Risk of Invasive Fungal Disease

FDA Alert

FDA approves Gardasil 9 for prevention of HPV

FDA Alert

First vaccine approved by FDA to prevent serogroup B Meningococcal disease

FDA Alert

Cubist Pharmaceuticals Issues Voluntary U.S. Recall Of Certain Lots Of CUBICIN

FDA Alert

FDA approves Orbactiv to treat skin infections

FDA Alert

FDA Approves Sivextro to Treat Skin Infections

FDA Alert

HIV/AIDS Update - Revised HHS Adult and Adolescent Antiretroviral Treatment Guidelines available

FDA Alert

FDA approves new treatment for hepatitis C virus

IDSA Continues to Recommend Antivirals for Influenza

IDSA continues to recommend the use of neuraminidase inhibitor antiviral drugs in the treatment of influenza.

Alert: FDA Statement about Product Quality of Parenteral Vancomycin Products

Drug Interactions: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs

FDA Alert

Drug Safety Communication: Statins and HIV or Hepatitis C Drugs - Interaction Increases Risk of Muscle Injury (Content)

FDA Alert

Drug Safety: Clostridum difficle-Associated Diarrhea Can Be Associated with Proton Pump Inhibitors (PPIs)

FDA Alert

Facts about Victrelis (boceprevir) and HIV protease inhibitors

Facts about Victrelis (boceprevir) and HIV protease inhibitors Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines peginterferon alfa and ribavirin to treat chronic (long lasting) hepatitis C infection in adults who have not

View All FDA Alerts

Infectious Diseases Society of America